Connect With Us
OSSGROW® is a medically approved personalised Bone Cell Therapy for the treatment of Avascular Necrosis, a painful bone disease.
Bone remodelling is an active and dynamic process that relies on the correct balance between bone resorption by osteoclasts and bone deposition by osteoblasts. When this equilibrium gets disturbed, the bone mass gets compromised leading to several bone diseases.
Avascular (lacking blood supply) Necrosis (death) is the death of bone tissue due to reduced or lack of blood supply. The incapacitated and hollow bone is unable to bear the body weight and eventually collapses.
Patients with AVN experience loss of mobility, become disabled and are forced to live a compromised life.
As per global estimates, more than 1 million people are affected with AVN each year.
AVN is also known as Osteonecrosis, Aseptic Necrosis, or Ischemic bone necrosis.
Learn about AVN with this e-book
The hip joint is the most commonly affected joint with AVN. The hip joint is made up of the femoral head (the ball) and the acetabulum (the socket).
AVN progresses rapidly and leads to complete joint destruction within 2 years upon diagnosis (X-ray & MRI).
Diagnosed with AVN? Share your reports here
This leaves the affected young population vulnerable to untimely hip replacement surgeries. New treatment modalities including biological products are on the rise.
Regrow® is pioneering its cutting edge research to bring an effective and durable solution for AVN.
Worried you might have AVN? Do this simple self-check shown in the video to determine if you might have AVN.
OSSGROW® is a cell-based biological product made up of patients' own bone cells called osteoblasts, which are responsible for a new bone formation.
Download OSSGROW® Treatment Guide
96% of patients did not experience any side effects or adverse events
Pain Improvement of 56% in 3 years
98% of patients are able to commute using public transport
96% patients are able to engage in physical activities like walking, running, jogging, gym training and cycling
96% patients did not need to undergo any additional surgery
Speak to our Medical Team now
Avascular Necrosis is the localized death of bone tissue due to interruption of blood supply as a result of injury/trauma or alcohol abuse or long-term use of steroids. This results in cellular imbalance of new bone formation and resorption that ultimately leads to bone death and collapse of the hip joint.
Osteoblasts are the major cellular component of bone tissue. Osteoblasts are bone-forming cells that comprise most of the bone matrix and regenerate new bone. In treating AVN, substitute the dead bone with newly formed bone tissue.
Cell therapy is curative treatment option for AVN that addressed the root cause of the disease. Osteoblast implantation helps to normalize natural bone remodeling process by forming healthy bone tissue.
In AVN, the cellular remodeling process of the bone is disturbed. Injected osteoblasts transform into mature bone tissue. New bone formation restores the cellular balance in the bone.
With the help of OSSGROW® treatment, the necrotic site of the bone is treated; it helps to regenerate tissue lost due to degenerative bone disease (avascular necrosis). OSSGROW® therapy can help regenerate all types of bone tissue lost due to degenerative bone disease.
The bone formed with OSSGROW® therapy slowly restores the structure and function of the hip joint, and you can perform daily physical activities such as exercise and sports after treatment.
Conditions that involve the death/deformity of bone cells such as AVN require treatment through bone cell therapy.
OSSGROW® is a bone-forming cell therapy option for curative treatment of early stages (up to Stage 3) of AVN. If the hip has collapsed or the necrotic zone is more than 50% of the hip joint, the outcomes are variable. However, patients with Stage 1 & 2 AVN have slightly better clinical outcomes.
Bone Cell Therapy is an Indian FDA and DCGI approved biologic and personalized drug, thus completely safe for administration into humans for clinical use. The product has been tested through successful completion of clinical trials in India.
As OSSGROW® is an autologous (patient’s own cell) cell therapy product, no risk can be associated with it, such as GVHD (Graft vs. host disease), Graft rejection, and chances of infection. Thus OSSGROW® is a completely safe cell therapy product.
In the clinical trial, no minor/ major product-related side effects were observed.
OSSGROW® is an autologous, totally safe, and clinically tested cell therapy product. There are no product-related adverse events observed during the clinical study.
There is no need to take any other medicine after OSSGROW® therapy. However, some people might experience pain, bruising or redness at the site of injection. Such effects of the injection are addressed by over-the-counter pain and anti-inflammatory drugs.
Yes, upon detailed analysis and screening by the orthopedic surgeon, the patient may undergo Bone Cell Therapy (OSSGROW®).
Yes, Bone Cell Therapy (OSSGROW®) is performed at all major private, government and state hospitals across all cities in India.
Hip Replacement is the process of replacing your original hip joint with an artificial implant (metal in most cases), whereas Bone Cell Therapy (OSSGROW®) is a completely natural and safe procedure which involves the implantation of the patient’s own bone cells.
The success rate of Bone Cell Therapy (OSSGROW®) is more than 80% in treating patients up to Stage 2 and more than 70% in Stage 3 of Avascular Necrosis.
Depending on patient to patient, one can start light weight bearing activities/movement within 1-3 weeks post operatively.
Yes, within 6-12 weeks one can return to all regular functional activities and exercises. Sports activities can be initiated at 12-24 weeks post-treatment depending upon your surgeon’s advice.
With the help of a proper rehabilitation programme, the patient will be able to walk with support within 1-3 weeks.
With the help of a proper rehabilitation programme, the patient will be able to walk without support within 3-6 weeks.
Yes, you can perform daily tasks such as household/office work/walk/sports after the OSSGROW® treatment.
With the help of a proper rehabilitation programme, the patient will be able to start cycling from the 12th week onwards.
For the cost of Bone Cell Therapy (OSSGROW®), please contact Regrow Biosciences® at 1800-209-0309 or put in an inquiry on our website (www.regrow.in) or Facebook page. Bone Cell Therapy (OSSGROW®) is covered under the cashless and reimbursement schemes for all major Private/Government and State Health Insurance Schemes.
To find a surgeon in your area, please contact Regrow Biosciences® at 1800-209-0309 or put in an inquiry on our website (www.regrow.in) or Facebook page.
This is a website that provides basic information on Avascular Necrosis (AVN) and Bone Cell Therapy (OSSGROW®) for the treatment of AVN. The intent of this website is to educate its users on AVN and Bone Cell Therapy (OSSGROW®). Your use of this website does not establish a doctor-patient relationship. The information provided on this website is intended for general knowledge and is not an attempt to practice medicine or provide specific medical advice or a substitute for professional medical advice or treatment for medical conditions and it should not be used to make a diagnosis or to replace or overrule a qualified healthcare provider’s judgment. Please consult your healthcare provider to diagnose any health problems and to answer any questions or concerns you may have regarding your condition.
All efforts have been made to provide information as accurate as possible. Although the content of this website is generally reviewed and Bone Cell Therapy (OSSGROW®) is approved by Indian FDA, we do not make any representation or warranties or take any responsibility or liability with respect to the accuracy, applicability, timeliness, fitness or completeness of the contents of this website, and any other warranty, express or implied, or for any errors or omissions in this website, for the results obtained from its use, or for any damage or loss caused or alleged to be caused by reliance on the information available on this website.